| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on August 17, 2006
From Centre for Clinical Neuroscience, St George’s University of London, London, UK. * To whom correspondence should be addressed. E-mail: hmarkus{at}sgul.ac.uk.
Background and Purpose--Endothelial dysfunction may play a causal role in cerebral small vessel disease (SVD). Asymmetric dimethylarginine (ADMA), a circulating endogenous inhibitor of nitric oxide, has been implicated in endothelial dysfunction, particularly in hyperhomocystinemia, a known risk factor for SVD. We determined if ADMA was elevated in SVD, correlated with disease severity, and interacted with homocysteine. Methods--ADMA and homocysteine levels were determined in 47 consecutive symptomatic SVD patients and 38 controls. SVD was graded by leukoariosis severity and number of lacunar infarcts. Results--Mean (and SD) ADMA was higher in SVD patients compared with controls (0.814 [0.145] versus 0.747 [0.184] µmol/L; P=0.014) after controlling for age, gender, vascular risk factors, and creatinine clearance. Additionally controlling for homocysteine had only a small effect on this relationship (P=0.055). Mean homocysteine was higher in SVD cases compared with controls (15.14 [5.59] versus 12.49 [4.15] µmol/L; P=0.035). Leukoariosis grade correlated positively with ADMA (P=0.026) and homocysteine (P=0.003). Lacunar grade correlated with homocysteine (P=0.017), but not ADMA. Conclusions--ADMA is independently associated with SVD and correlates with leukoariosis severity.
Accepted on September 13, 2006
Asymmetric Dimethylarginine in Cerebral Small Vessel Disease
Usman Khan MRCP;
Related Article:
Stroke 2007 38: 395-397.
This article has been cited by other articles:
![]() |
M. Gomis, T. Sobrino, A. Ois, M. Millan, A. Rodriguez-Campello, N. P. de la Ossa, R. Rodriguez-Gonzalez, J. Jimenez-Conde, E. Cuadrado-Godia, J. Roquer, et al. Plasma {beta}-Amyloid 1-40 Is Associated With the Diffuse Small Vessel Disease Subtype Stroke, October 1, 2009; 40(10): 3197 - 3201. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Pikula, R. H. Boger, A. S. Beiser, R. Maas, C. DeCarli, E. Schwedhelm, J. J. Himali, F. Schulze, R. Au, M. Kelly-Hayes, et al. Association of Plasma ADMA Levels With MRI Markers of Vascular Brain Injury: Framingham Offspring Study Stroke, September 1, 2009; 40(9): 2959 - 2964. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. B. Gorelick and J. V. Bowler Advances in Vascular Cognitive Impairment 2007 Stroke, February 1, 2008; 39(2): 279 - 282. [Full Text] [PDF] |
||||
![]() |
H. Dayoub, R. N. Rodionov, C. Lynch, J. P. Cooke, E. Arning, T. Bottiglieri, S. R. Lentz, and F. M. Faraci Overexpression of Dimethylarginine Dimethylaminohydrolase Inhibits Asymmetric Dimethylarginine-Induced Endothelial Dysfunction in the Cerebral Circulation Stroke, January 1, 2008; 39(1): 180 - 184. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. S. Markus Genes, endothelial function and cerebral small vessel disease in man Exp Physiol, January 1, 2008; 93(1): 121 - 127. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Tsuda Asymmetric Dimethylarginine and Hypertension in Cerebral Small Vessel Disease Stroke, July 1, 2007; 38(7): e48 - e48. [Full Text] [PDF] |
||||
![]() |
U. Khan and H. S. Markus Response to Letter by Tsuda Stroke, July 1, 2007; 38(7): e49 - e49. [Full Text] [PDF] |
||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2007 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |